Cardiac Magnetic Resonance Imaging in Hemodialysis Patients
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Left ventricular mass
研究概览
简要总结
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
详细描述
Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hemodialysis patients
排除标准
- •non compliance
- •hyperkalemia
- •pregnancy
- •expected survival less than 9 months
研究组 & 干预措施
1 group - no arms
no arm just error message
干预措施: Spironolactone (Drug)
结局指标
主要结局
Left ventricular mass
时间窗: 9 months
次要结局
未报告次要终点
研究者
Dawnmarie DeFazio
Nephrolgist, Co-Investigator
West Penn Allegheny Health System